These results suggest that DR5 is a potential molecular target for PEITC-induced apoptosis in oral cancer via p38 MAPK.

These results suggest that Tol could be a potent anti-cancer drug for YD-15 MEC cells that acts by regulating the MCL-1 protein.

The patients were reported with no middle ear injury prior to the radiotherapy, however, suffered from the injury after the treatment. Methods Descriptive study with clinical intervention In this study, we examined all Head and Neck Cancer patients before and after radiotherapy, thus found that 148 patients have suffered from middle-ear damage post-treatment. These patients were then divided into two groups: Group A included those with OME or tympanosclerosis who later undergo myringotomy and tympanotomy, and group B consists of those with Eustachian dysfunction who did not require any intervened treatment. The patients in those two groups were examined and monitored for one month after the radiotherapy using otoscopy, audiometry, and tympanometry test. Results In this study, we reported the average age of 148 HNC patients to